Pharvaris N.V. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
PHVS Nasdaq 2830 pharvaris.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Pharvaris N.V.

Bank of America backs Pharvaris on breakthrough for rare swelling disease - Oct 26th, 2026 5:00 pm
Norwegian downgraded, Skydance upgraded: Wall Street's top analyst calls - Oct 23rd, 2026 7:57 am
BioCryst (BCRX) Trades at Just 11x Forward Earnings. Is the Market Pricing In Trouble? - Oct 15th, 2026 12:05 pm
Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet - Oct 8th, 2026 4:35 pm
Could Real-World HAE Oral Preference Data Be a Pivotal Signal for Pharvaris' (PHVS) Strategy? - Oct 8th, 2026 9:10 am
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy - Oct 5th, 2026 4:50 am
What Does Pharvaris (PHVS) Phase 3 HAE Success Mean Now? - Sep 19th, 2026 9:12 am
BioCryst Eyes $1B Rare-Disease Future Through External Innovation - Sep 18th, 2026 8:01 pm
PHVS Stock Rises 10% in a Month: What Is Driving the Rally? - Sep 15th, 2026 7:50 am
Pharvaris (PHVS) Reports an 83% HAE Attack-Rate Reduction. Can Oral Convenience Win? - Sep 10th, 2026 5:25 pm
BCRX Stock Heads For Fifth Straight Day In The Red – RBC Capital Says BioCryst Faces A ‘Challenging Near-Term Outlook’ - Sep 10th, 2026 9:52 am
BioCryst Pharmaceuticals Faces Competitive Pressure in Hereditary Angioedema Treatment, RBC Says - Sep 10th, 2026 9:42 am
Pharvaris Could Gain Hereditary Angioedema Market Share on Deucrictibant XR Data, RBC Says - Sep 9th, 2026 9:18 am
Pharvaris charts approval course for swelling disorder drug on Phase III win - Sep 9th, 2026 5:33 am
BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease - Sep 8th, 2026 5:24 pm
Biotech Stocks, With 'Blowout' And 'Bull Case' Results, Rocket To Record Highs - Sep 8th, 2026 2:24 pm
These 2 Biotech Stocks Hit Record Highs Today – What’s Driving The Rallies? - Sep 8th, 2026 11:53 am
Top Midday Gainers - Sep 8th, 2026 11:27 am
Pharvaris Shares Surge 27% After Deucrictibant Phase 3 Trial Meets Primary Endpoint - Sep 8th, 2026 6:56 am
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks - Sep 8th, 2026 4:50 am